CAS: 14533-63-2; Sodium 1-Propanesulfonate

相似化合物

2386-54-1 304672-01-3 22767-49-3

上下游产品

CAS号107-08-4 1-碘丙烷 | CAS号10147-36-1 丙基磺酰氯 | CAS号10147-36-1 丙基磺酰氯 | CAS号1561-97-3 2-hydroxy-propa... | CAS号15909-83-8 3-羟基丙磺酸

专利信息

专利号:WO-2012030642-A2
优先权日:2010-09-02
标 题:Microbially-mediated method for synthesis of non-oxide semiconductor nanoparticles

专利号:CN-102531981-A
优先权日:2012-01-18
标 题 :An improved mercaptolation method for the synthesis of sodium 2,3-dimercaptopropanesulfonate

专利号:CN-118292003-A
优先权日:2023-01-05
标题 :Electrochemical Synthesis of 1,3,6-Hexanetrinitrile

专利号:WO-2023033017-A1
优先权日:2021-09-01
标 题 :Method for producing ganirelix or salt thereof
发明人：YANO SHINYA; MATSUMOTO SUGURU
权利人:SEKISUI MEDICAL CO LTD
摘要:Provided is a novel method for producing ganirelix by liquid phase peptide synthesis method.　The present invention pertains to a method that is for producing ganirelix or a salt thereof by a liquid phase peptide synthesis method, and that uses a binding product between a compound represented by formulae (1)-(3) (where R1 and R2 each represent Boc, Cbz, Troc, Alloc, Trt, Mmt, Teoc, Phth, SES, or ivDde, and R3 represents an amino-protecting group) and a carrier for liquid phase peptide synthesis, as a raw material for a condensation reaction of the third and fifth diethyl homoarginine residues from the C terminal.

专利号:US-6531507-B1
优先权日:2000-06-09
标 题 :Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
发明人：PFLAUM ZLATKO; KERC JANEZ
权利人:LEK PHARMACEUTICALS
摘要:Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. n The aforementioned active substances may be destabilized by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions. n The present invention relates to a HMG-CoA reductase inhibitor which is stabilized by forming a homogeneous composition with a buffering substance or a basifying substance. This homogeneous composition is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia.

专利号:US-6806290-B2
优先权日:2000-06-09
标题:Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
发明人：PFLAUM ZLATKO; KERC JANEZ
权利人:LEK PHARMACEUTICALS
摘要:Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilized by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions. The present invention relates to a HMG-CoA reductase inhibitor which is stabilized by forming a homogeneous composition with a buffering substance or a basifying substance. This homogeneous composition is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia.